SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s SG&A?
- Tarsus Pharmaceuticals, Inc. (TARS) reported SG&A of $136.43M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s SG&A changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s SG&A increased by 60.5% year-over-year, from $85M to $136.43M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s SG&A?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s SG&A has grown at a 111.8% compound annual growth rate (CAGR), from $44.95M to $427.32M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.